← All trials
NCT04359303
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Nov 30, 2020
- Completion date
- Dec 31, 2020
- First posted
- Apr 24, 2020
- Last posted
- May 19, 2020
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Católica San Antonio de MurciaLead sponsor
- Universidad Católica San Antonio de MurciaSponsor investigator
- Sociedad Española de OzonoterapiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.